The Hancock Jaffe Laboratories Inc (HJLI) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HJLI. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for HJLI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedHJLI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Hancock Jaffe Laboratories Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HJLI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HJLI.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Data Not Found! |
When did it IPO
2018
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$32.4M
In 2023, HJLI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HJLI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will rebrand as enVVeno Medical Corporation (ticker: NVNO) on October 1, focusing exclusively on the VenoValve for venous disease treatment.
Why It Matters - The rebranding and strategic focus on the VenoValve may enhance investor confidence, potentially driving stock performance and attracting new interest in the company's innovative approach to venous disease.
Summary - Hancock Jaffe Laboratories CEO Robert Berman will participate in a webinar on September 27, 2021, at 1:00 PM ET, hosted by Ladenburg Thalmann, focusing on venous disease treatments.
Why It Matters - The webinar could provide insights into Hancock Jaffe's strategies and innovations, influencing investor sentiment and potential stock performance.
Summary - Hancock Jaffe will rebrand as enVVeno Medical Corporation (NASDAQ: NVNO) on October 1, 2021, focusing on venous disease and advancing the VenoValveยฎ. A second product is expected in mid-2022.
Why It Matters - The rebranding to enVVeno Medical Corporation and focus on venous disease could attract investors seeking growth in a specialized medical sector, potentially increasing stock value and market interest.
Summary - Hancock Jaffe Laboratories, Inc. will hold a corporate update conference call with a live video webcast on September 21, 2021, at 4:30 p.m. ET.
Why It Matters - The conference call indicates potential updates on company performance and product developments, which can influence stock prices and investor sentiment for Hancock Jaffe Laboratories.
Summary - Hancock Jaffe Laboratories, Inc. announced a $20 million registered direct offering, selling 2,540,650 shares at $7.8720 each to a fund managed by Perceptive Advisors.
Why It Matters - Hancock Jaffe's $20 million capital raise enhances liquidity for growth and innovation, signaling confidence from investors like Perceptive Advisors, which may positively influence stock performance.
Summary - Hancock Jaffe Laboratories, focused on bioprosthetics for cardiovascular diseases, received IDE approval in April 2021 to start a pivotal trial for its VenoValve product in the U.S.
Why It Matters - Hancock Jaffe's IDE approval for VenoValve indicates potential market entry and revenue growth, signaling a promising advancement in cardiovascular treatments that could enhance investor confidence.